Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia

Blood

Volumn 111, Issue 4, 2008, Pages 2388-2391

  Poncet, Delphine ^a,b   Belleville, Aurélie ^a,b   De Roodenbeke, Claire T'Kint ^a   De Climens, Aude Roborel ^a   Simon, Elsa Ben ^a   Merle Beral, Hélène ^c   Callet Bauchu, Evelyne ^a,b   Salles, Gilles ^a,b   Sabatier, Laure ^d   Delic, Jozo ^d   Gilson, Eric ^a,b,e  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSTITUT DE RADIOBIOLOGIE CELLULAIRE ET MOLÉCULAIRE   (France)

^e Univ Claude Bernard   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DYSKERIN; MRE11 PROTEIN; PROTEIN; PROTEIN HEST1A; PROTEIN HRAP1; PROTEIN KU80; PROTEIN POT1; PROTEIN RPA1; PROTEIN TIN2; PROTEIN TPP1; RAD50 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; UNCLASSIFIED DRUG;

ARTICLE; B CELL LEUKEMIA; CANCER GENETICS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE; TRANSCRIPTOMICS;

EID: 41349099406     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-09-111245     Document Type: Article

References (24)

1. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science. 2007;315:1850-1853.
2. Gilson E, Geli V. How telomeres are replicated. Nat Rev Mol Cell Biol. 2007;8:825-838.
3. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene. 2002;21:680-687.
4. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
5. Nakanishi K, Kawai T, Kumaki F, et al. Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin Cancer Res. 2003;9:1105-1111.
6. Hsu CP, Lee LW, Shai SE, Chen CY. Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus. World J Gastroenterol. 2005;11:6941-6947.
7. Lin X, Gu J, Lu C, Spitz MR, Wu X. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006;12:5720-5725.
8. Salhab M, Jiang WG, Newbold RF, Mokbel K. The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinicopathological parameters and clinical outcome. Breast Cancer Res Treat. 2007 [Epub ahead of print].
9. Swiggers SJ, Kuijpers MA, de Cort MJ, Beverloo HB, Zijlmans JM. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes Chromosomes Cancer. 2006;45:247-256.
10. Bellon M, Datta A, Brown M, et al. Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia. Int J Cancer. 2006;119:2090-2097.
11. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21:841-894.
12. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995;85:2315-2320.
13. Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood. 2004;103:375-382.
14. Ricca I, Rocci A, Drandi D, et al. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia. 2007;21:697-705.
15. Callet-Bauchu E, Rimokh R, Tigaud I, et al. dic(4;17)(p11;p11): a new recurrent chromosomal abnormality in chronic B-lymphoid disorders. Genes Chromosomes Cancer. 1996;17:185-190.
16. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
17. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
18. Bechter OE, Eisterer W, Dlaska M, Kuhr T, Thaler J. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp Hematol. 2002;30:26-33.
19. Amiel A, Goldzak G, Gaber E, et al. Random aneuploidy and telomere capture in chronic lymphocytic leukemia and chronic myeloid leukemia patients. Cancer Genet Cytogenet. 2005;163:12-16.
20. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755-764.
21. Ladetto M, Compagno M, Ricca I, et al. Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. Blood. 2004;103:4644-4649.
22. El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood. 2005;105:1742-1749.
23. Wang F, Podell ER, Zaug AJ, et al. The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature. 2007;445:506-510.
24. Reichenbach P, Hoss M, Azzalin CM, Nabholz M, Bucher P, Lingner J. A human homolog of yeast Est1 associates with telomerase and uncaps chromosome ends when overexpressed. Curr Biol. 2003;13:568-574.